首页> 外文OA文献 >Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

【2h】

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

机译：硒替尼（AZD6244; ARRY-142886）中冬季-131难治性乳头状甲状腺癌中的II期疗效和药物研究，有或没有卵泡元件

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D. Neil Hayes; Amy S. Lucas; Tawee Tanvetyanon; Monika K. Krzyzanowska; Christine H. Chung; Barbara A. Murphy; Jill Gilbert; Ranee Mehra; Dominic T. Moore; Arif Sheikh; Janelle Hoskins; Michele C. Hayward; Ni Zhao; Wendi OConnor; Karen E. Weck; Roger B. Cohen; Ezra E.W. Cohen;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements [J] . HayesD.N., LucasA.S., TanvetyanonT., Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第7期

机译：selumetinib（AZD6244; ARRY-142886）在碘131难治性甲状腺乳头状癌伴或不伴滤泡成分的II期疗效和药物基因组学研究
2. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements [J] . HayesD.N., LucasA.S., TanvetyanonT., Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第7期

机译：selumetinib（AZD6244; ARRY-142886）在碘131难治性甲状腺乳头状癌伴或不伴滤泡成分的II期疗效和药物基因组学研究
3. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. [J] . Gy?rgy Bodoky, Constanta Timcheva, David Robert Spigel, Investigational new drugs. . 2012,第3期

机译：II期开放标签随机研究，评估一线吉西他滨治疗失败的晚期或转移性胰腺癌患者中selumetinib（AZD6244 [ARRY-142886]）与卡培他滨的疗效和安全性。
4. Imaging of follicular variant papillary thyroid carcinoma in a rodent model using spectral-based quantitative ultrasound techniques [C] . Lavarello R.J., Ridgway B., Sarwate S., IEEE International Symposium on Biomedical Imaging: From Nano to Macro . 2013

机译：使用基于光谱的定量超声技术对啮齿动物模型中的滤泡性甲状腺乳头状癌进行成像
5. Mechanistic study of fragile site instability by investigating RET/PTC rearrangements, a common cause of papillary thyroid carcinoma. [D] . Dillon, Laura Williams. 2012

机译：通过研究RET / PTC重排，即甲状腺乳头状癌的常见原因，对脆弱的部位不稳定进行机理研究。
6. Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements [O] . D. Neil Hayes, Amy S. Lucas, Tawee Tanvetyanon, -1

机译：阶段II有效性和司美替尼的药物基因组学研究（aZD6244; aRRY-142886）在碘-131耐火材料甲状腺乳头状癌具有或不具有滤泡元素
7. Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 ARRY-142886) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy [O] . György Bodoky, Constanta Timcheva, David Robert Spigel, 2011

机译：错误至：II期开放标签随机研究，以评估Selumetinib（AZD6244 Arry-142886的疗效和安全性与患有失败的一线吉西他滨治疗失败或转移性胰腺癌的患者

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

著录项

引文网络

相似文献

相关主题

期刊订阅